132.13 USD
+4.88 (+3.83%)
132.13 USD
0 (0%)
ILMN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. ILMN scores excellent on profitability, but there are some minor concerns on its financial health. ILMN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ILMN was profitable.
ILMN had a positive operating cash flow in the past year.
In multiple years ILMN reported negative net income over the last 5 years.
In the past 5 years ILMN always reported a positive cash flow from operatings.
1.2 Ratios
ILMN has a Return On Assets of 11.38%. This is amongst the best in the industry. ILMN outperforms 91.23% of its industry peers.
With an excellent Return On Equity value of 29.53%, ILMN belongs to the best of the industry, outperforming 96.49% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 16.40%, ILMN belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ILMN has a better Profit Margin (16.39%) than 89.47% of its industry peers.
ILMN has a Operating Margin of 20.41%. This is amongst the best in the industry. ILMN outperforms 85.96% of its industry peers.
In the last couple of years the Operating Margin of ILMN has declined.
With an excellent Gross Margin value of 66.74%, ILMN belongs to the best of the industry, outperforming 87.72% of the companies in the same industry.
ILMN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ILMN is creating some value.
ILMN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ILMN has more shares outstanding
ILMN has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.23 indicates that ILMN is not in any danger for bankruptcy at the moment.
ILMN's Altman-Z score of 4.23 is fine compared to the rest of the industry. ILMN outperforms 77.19% of its industry peers.
ILMN has a debt to FCF ratio of 1.99. This is a very positive value and a sign of high solvency as it would only need 1.99 years to pay back of all of its debts.
ILMN has a better Debt to FCF ratio (1.99) than 87.72% of its industry peers.
ILMN has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
ILMN has a Debt to Equity ratio (0.42) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.23 |
ROIC/WACC1.59
WACC10.31%
2.3 Liquidity
ILMN has a Current Ratio of 1.43. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.43, ILMN is doing worse than 78.95% of the companies in the same industry.
A Quick Ratio of 1.12 indicates that ILMN should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.12, ILMN is doing worse than 70.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 152.02% over the past year.
The earnings per share for ILMN have been decreasing by -17.93% on average. This is quite bad
ILMN shows a decrease in Revenue. In the last year, the revenue decreased by -2.32%.
Measured over the past years, ILMN shows a small growth in Revenue. The Revenue has been growing by 4.29% on average per year.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
ILMN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.49% yearly.
ILMN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.93% yearly.
EPS Next Y96.04%
EPS Next 2Y44.34%
EPS Next 3Y33.86%
EPS Next 5Y24.49%
Revenue Next Year-0.86%
Revenue Next 2Y0.6%
Revenue Next 3Y2.25%
Revenue Next 5Y3.93%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ILMN is valuated quite expensively with a Price/Earnings ratio of 30.31.
ILMN's Price/Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 71.93% of the companies in the same industry.
When comparing the Price/Earnings ratio of ILMN to the average of the S&P500 Index (26.28), we can say ILMN is valued inline with the index average.
ILMN is valuated quite expensively with a Price/Forward Earnings ratio of 25.89.
ILMN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 77.19% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.52, ILMN is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.31 | ||
| Fwd PE | 25.89 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ILMN indicates a rather cheap valuation: ILMN is cheaper than 80.70% of the companies listed in the same industry.
87.72% of the companies in the same industry are more expensive than ILMN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.19 | ||
| EV/EBITDA | 17.33 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ILMN has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ILMN's earnings are expected to grow with 33.86% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y44.34%
EPS Next 3Y33.86%
5. Dividend
5.1 Amount
No dividends for ILMN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
132.13
+4.88 (+3.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.82%
Inst Owner Change1.59%
Ins Owners0.18%
Ins Owner Change-0.36%
Market Cap20.19B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts72.86
Price Target123.49 (-6.54%)
Short Float %4.29%
Short Ratio3.58
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)8.18%
PT rev (3m)7.8%
EPS NQ rev (1m)-0.46%
EPS NQ rev (3m)2.73%
EPS NY rev (1m)1.32%
EPS NY rev (3m)4.19%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)0.63%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.31 | ||
| Fwd PE | 25.89 | ||
| P/S | 4.71 | ||
| P/FCF | 20.19 | ||
| P/OCF | 17.99 | ||
| P/B | 8.48 | ||
| P/tB | 19.36 | ||
| EV/EBITDA | 17.33 |
EPS(TTM)4.36
EY3.3%
EPS(NY)5.1
Fwd EY3.86%
FCF(TTM)6.54
FCFY4.95%
OCF(TTM)7.34
OCFY5.56%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.32
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.23 |
F-Score7
WACC10.31%
ROIC/WACC1.59
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y96.04%
EPS Next 2Y44.34%
EPS Next 3Y33.86%
EPS Next 5Y24.49%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-0.86%
Revenue Next 2Y0.6%
Revenue Next 3Y2.25%
Revenue Next 5Y3.93%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year35.78%
EBIT Next 3Y17.09%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ILMN.
What is the valuation status for ILMN stock?
ChartMill assigns a valuation rating of 6 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
How financially healthy is ILLUMINA INC?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
Can you provide the expected EPS growth for ILMN stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 96.04% in the next year.